A multi-cohort, open-label, phase 1/2 study (ARROW) study (NCT03037385) tested the potential activity and safety of the pralsetinib in both previously treated and untreated patients with RET-altered metastatic NSCLC [116]. This evidence concerns the gene RET and non-small cell lung carcinoma.